Why SPDR Biotech ETF (XBI) fell 2.03%

SPDR Biotech ETF (XBI) fell 2.03% on November 17, 2026 — FDA rejection of a closely watched cancer drug hits biotech.

What happened

The FDA declined to approve one of biotech's most closely watched cancer drugs, a rejection the FT says is a blow to China's biotech industry because the drug was developed there.

Why it moved

A high-profile rejection forces the market to lower its approval odds for similar late-stage assets, which compresses multiples across a basket of small and mid-cap biotechs.

Why it matters

This sits inside a Healthcare & Biotech theme where GLP-1 obesity adoption and a small-cap biotech bid had lifted Lilly and Hims.

What would break the thesis

If the company secures a clear path to approval through new data or a quick resubmission, the read-through fades and the group can recover.

Sources

Trade XBI 24/7 →